Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
26.96
+0.56 (2.12%)
Nov 21, 2024, 1:13 PM EST - Market open
Company Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.
Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity.
It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Celldex Therapeutics, Inc.
Country | United States |
Founded | 1983 |
IPO Date | Mar 10, 2008 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 160 |
CEO | Anthony Marucci |
Contact Details
Address: Perryville III Building, Suite 220 Hampton, New Jersey 08827 United States | |
Phone | 908 200 7500 |
Website | celldex.com |
Stock Details
Ticker Symbol | CLDX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000744218 |
CUSIP Number | 15117B202 |
ISIN Number | US15117B2025 |
Employer ID | 13-3191702 |
SIC Code | 2835 |
Key Executives
Name | Position |
---|---|
Anthony S. Marucci M.B.A. | Founder, President, Chief Executive Officer and Director |
Dr. Tibor Keler Ph.D. | Founder, Chief Scientific Officer and Executive Vice President |
Dr. Margo Heath-Chiozzi M.D. | Senior Vice President of Regulatory Affairs |
Dr. Diane C. Young M.D. | Senior Vice President and Chief Medical Officer |
Prof. Joseph P. Schlessinger Ph.D. | Co-Founder and Member of Scientific Advisory Board |
Sarah Cavanaugh | Senior Vice President of Corporate Affairs and Administration |
Freddy A. Jimenez Esq. | Senior Vice President and General Counsel |
Dr. Ronald A. Pepin | Chief Business Officer and Senior Vice President |
Elizabeth Crowley | Chief Product Development Officer and Senior Vice President |
Dr. Richard M. Wright Ph.D. | Chief Commercial Officer and Senior Vice President |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 6, 2024 | 10-Q | Quarterly Report |
Nov 6, 2024 | 8-K | Current Report |
Aug 8, 2024 | 10-Q | Quarterly Report |
Aug 8, 2024 | 8-K | Current Report |